Estimated MDR/RR-TB cases among notified pulmonary TB cases (2015)

**Southern African Tuberculosis and Health Systems Support (SATBHSS) Project**

**Lesotho**
- New and relapse cases in 2014: 70%
- Second-line treatment (MDR/RR-TB) in 2013: 63%

**Malawi**
- New and relapse cases in 2014: 85%
- Second-line treatment (MDR/RR-TB) in 2013: 53%

**Mozambique**
- New and relapse cases in 2014: 89%
- Second-line treatment (MDR/RR-TB) in 2013: 52%

**Zambia**
- New and relapse cases in 2014: 85%
- Second-line treatment (MDR/RR-TB) in 2013: 33%

---

**Source**: World Health Organization (WHO) 2016 Global Tuberculosis Report
TB Financing 2016

Resources required in 2016 for inpatient and outpatient care for Drug Susceptible TB (DS-TB), Multi-Drug Resistant TB (MDR-TB) and TB in US$ Millions (2016)

Lesotho
- DS-TB Care: 0.30
- MDR-TB Care: 0.11
- TB Care: 6.8

Malawi
- DS-TB Care: -
- MDR-TB Care: -
- TB Care: -

Mozambique
- DS-TB Care: 3.4
- MDR-TB Care: 0.13
- TB Care: 27

Zambia
- DS-TB Care: 2.00
- MDR-TB Care: 0.61
- TB Care: 13

Funding Source
- Lesotho: 12% domestic, 19% international and 69% unfunded (deficit)
- Malawi: 10% domestic, 90% international and 0% unfunded (deficit)
- Mozambique: 4% domestic, 72% international and 24% unfunded (deficit)
- Zambia: 9% domestic, 51% international and 40% unfunded (deficit)